Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

Azenosertib posts strong early OS and response data in platinum-resistant ovarian cancer

Zentalis’ WEE1 inhibitor azenosertib showed encouraging survival and response data in Cyclin E1-positive platinum-resistant ovarian cancer.

GSK’s B7-H4 ADC mo-rez showed durable responses in platinum-resistant ovarian cancer, with phase 3 studies now moving forward.

Dana-Farber has appointed Eliezer Van Allen, MD, as its inaugural chief AI officer to oversee AI strategy, governance,…

Precision medicine is advancing fast, but clinical translation remains uneven. A World Journal of Gastroenterology review calls for…

Rilvegostomig advances into first-in-human phase I/II testing in metastatic non–small cell lung cancer, a setting with persistent unmet…

JCO pilot study tests whether add-on beta-sitosterol can influence treatment response in a randomized, double-blind, placebo-controlled design.

ASCO abstract examines tumor board-based multi-agent LLMs with guideline retrieval for hepatocellular carcinoma reasoning, but gives no performance…

A prospective cross-sectional study examines basic palliative care assessments in urological oncology, where symptom burden and supportive needs…

A MedStar Health Network study examines whether androgen receptor CAG repeat polymorphisms correlate with prostate cancer aggressiveness at…

GBD 2023 estimates show 377,000 childhood cancer cases and 144,000 deaths in 2023, with the heaviest mortality burden…

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds